Cabozantinib: Mechanism of action, efficacy and indications

被引：30

作者：

Cochin, Valerie ^{[1
]}

Gross-Goupil, Marine ^{[1
]}

Ravaud, Alain ^{[1
,2
]}

Godbert, Yann ^{[3
]}

Le Moulec, Sylvestre ^{[3
]}

机构：

[1] Hop St Andre, Ctr Hosp Univ Bordeaux, 01 Rue Jean Burguet, F-33075 Bordeaux, France

[2] Univ Bordeaux, 146 Rue Leo Saignat, F-33076 Bordeaux, France

[3] Ctr Lutte Canc Bordeaux, Inst Bergonie, 229 Cours Argonne, F-33076 Bordeaux, France

来源：

BULLETIN DU CANCER | 2017年 / 104卷 / 05期

关键词：

Cabozantinib; MET receptor; Medullary thyroid cancer; Advanced cell renal carcinoma; Prostate cancer; Lung cancer; THYROID ASSOCIATION GUIDELINES; PHASE-III; CANCER; XL184; MET; EVEROLIMUS; PREDNISONE; RESISTANCE; INHIBITORS; MUTATIONS;

D O I：

10.1016/j.bulcan.2017.03.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cabozantinib is an oral multiple tyrosine kinase receptor inhibitor (ITK): VEGFR2, c-MET and RET. Inhibition of VEGFR and c-MET decrease resistance of VEGFR inhibitor via c-MET axis. Cabozantinib improve progression-free survival (PFS) in progressive metastatic medullary thyroid cancer (MTC): 4 months in the placebo group and 11.2 months in the cabozantinib group (P < 0.001) in all patient subgroups including those with or without prior ITK and RET mutation status. Cabozantinib increased overall survival (OS) compared with everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR ITK treatment: 21.4 months in cabozantinib group and 16.5 months in everolimus group (P < 0.0003). Cabozantinib obtained the AMM for the treatment of progressive metastatic MTC and advanced renal cell carcinoma. Cabozantinib is a new option in the treatment of MTC by inclusion in therapeutic trials (no payment in this indication) and advanced renal cell carcinoma (hospital delivery). Its tolerance is similar to anti-angiogenic therapies and justifies an optimal management of the secondary effect.

引用

页码：393 / 401

页数：9

共 38 条

[1]

[Anonymous], ASCO M ABSTR S

[2] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression [J].

Awad, Mark M. ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Savukoski, Daniel O. ;

Hall, Dimity ;

Shivdasani, Priyanka ;

Heng, Jennifer C. ;

Dahlberg, Suzanne E. ;

Anne, Pasi A. J. ;

Verma, Suman ;

Christensen, James ;

Hammerman, Peter S. ;

Sholl, Lynette M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) :721-+

[3] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[4] A phase I study of cabozantinib (XL184) in patients with renal cell cancer [J].

Choueiri, T. K. ;

Pal, S. K. ;

McDermott, D. F. ;

Morrissey, S. ;

Ferguson, K. C. ;

Holland, J. ;

Kaelin, W. G. ;

Dutcher, J. P. .

ANNALS OF ONCOLOGY, 2014, 25 (08) :1603-1608

[5] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[6] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

[7]

Drilon AE, 2015, J CLIN ONCOL, V33

[8] Cabozantinib in Progressive Medullary Thyroid Cancer [J].

Elisei, Rossella ;

Schlumberger, Martin J. ;

Mueller, Stefan P. ;

Schoffski, Patrick ;

Brose, Marcia S. ;

Shah, Manisha H. ;

Licitra, Lisa ;

Jarzab, Barbara ;

Medvedev, Viktor ;

Kreissl, Michael C. ;

Niederle, Bruno ;

Cohen, Ezra E. W. ;

Wirth, Lori J. ;

Ali, Haythem ;

Hessel, Colin ;

Yaron, Yifah ;

Ball, Douglas ;

Nelkin, Barry ;

Sherman, Steven I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (29) :3639-+

[9] Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Porta, C. ;

Schmidinger, M. ;

Rioux-Leclercq, N. ;

Bex, A. ;

Khoo, V. ;

Gruenvald, V. ;

Horwich, A. .

ANNALS OF ONCOLOGY, 2016, 27 :v58-v68

[10]

Graham TJ, 2014, JNCI-J NATL CANCER I, P106

← 1 2 3 4 →